Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma
Although epidermal growth factor receptor (EGFR) is often over-expressed in soft tissue sarcoma (STS), a phase II trial using an EGFR inhibitor gefitinib showed a low response rate. This study identified a new secondary resistance mechanism of gefitinib in STS, and developed new strategies to improv...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Impact Journals LLC
2016
|
| Online Access: | http://hdl.handle.net/20.500.11937/9373 |